Aclaris Therapeutics Inc. (NASDAQ:ACRS) insider Kamil Ali-Jackson sold 1,841 shares of the business’s stock in a transaction dated Wednesday, September 28th. The shares were sold at an average price of $24.66, for a total value of $45,399.06. Following the completion of the transaction, the insider now owns 77,798 shares in the company, valued at $1,918,498.68. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.
Kamil Ali-Jackson also recently made the following trade(s):
- On Friday, August 26th, Kamil Ali-Jackson sold 3,738 shares of Aclaris Therapeutics stock. The shares were sold at an average price of $20.35, for a total value of $76,068.30.
Shares of Aclaris Therapeutics Inc. (NASDAQ:ACRS) opened at 25.49 on Tuesday. Aclaris Therapeutics Inc. has a 52-week low of $10.99 and a 52-week high of $33.88. The company has a 50 day moving average price of $22.64 and a 200-day moving average price of $20.24. The stock’s market capitalization is $545.87 million.
Aclaris Therapeutics (NASDAQ:ACRS) last posted its earnings results on Thursday, August 11th. The company reported ($0.62) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.61) by $0.01. On average, analysts predict that Aclaris Therapeutics Inc. will post ($2.60) earnings per share for the current fiscal year.
Large investors have recently bought and sold shares of the stock. Vivo Capital LLC acquired a new stake in Aclaris Therapeutics during the first quarter worth approximately $79,427,000. FIL Ltd acquired a new stake in Aclaris Therapeutics during the second quarter worth approximately $13,801,000. Vanguard Group Inc. boosted its stake in Aclaris Therapeutics by 147.6% in the second quarter. Vanguard Group Inc. now owns 419,184 shares of the company’s stock worth $7,743,000 after buying an additional 249,888 shares during the period. BlackRock Fund Advisors boosted its stake in Aclaris Therapeutics by 59.7% in the second quarter. BlackRock Fund Advisors now owns 234,696 shares of the company’s stock worth $4,335,000 after buying an additional 87,739 shares during the period. Finally, State Street Corp boosted its stake in Aclaris Therapeutics by 64.8% in the second quarter. State Street Corp now owns 120,010 shares of the company’s stock worth $2,217,000 after buying an additional 47,179 shares during the period. Hedge funds and other institutional investors own 71.39% of the company’s stock.
Several brokerages have recently commented on ACRS. Zacks Investment Research downgraded Aclaris Therapeutics from a “hold” rating to a “sell” rating in a research report on Friday. JMP Securities began coverage on Aclaris Therapeutics in a research report on Friday. They issued an “outperform” rating and a $34.00 price objective on the stock. Jefferies Group boosted their price objective on Aclaris Therapeutics from $23.00 to $31.00 and gave the company a “buy” rating in a research report on Monday, September 19th. Finally, Guggenheim began coverage on Aclaris Therapeutics in a research report on Friday, June 10th. They issued a “buy” rating and a $35.00 price objective on the stock. One research analyst has rated the stock with a sell rating and five have given a buy rating to the stock. Aclaris Therapeutics currently has a consensus rating of “Buy” and a consensus target price of $31.80.
About Aclaris Therapeutics
Aclaris Therapeutics, Inc is a United States-based clinical-stage specialty pharmaceutical company. The Company is focused on identifying, developing and commercializing differentiated therapies in dermatology. The Company’s drug candidate, A-101 is being developed as an in-office treatment for seborrheic keratosis, a non-cancerous skin tumor, as well as for other cutaneous indications, such as common warts.
Receive News & Ratings for Aclaris Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aclaris Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.